Abstract
Listeria monocytogenes, a gram-positive rod, infects the central nervous system in neonates, pregnant woman and those immunosuppressed by naturally occurring illnesses and by therapeutic agents, including agents such as infliximab. We report here the first published case of Listeriosis complicating Infliximab therapy in Crohn's disease in Australia.
Highlights
A 45-year-old Caucasian woman presented to the emergency department with a two-day history of increasing right lower limb weakness
The regimen was modified to Ampicillin 8 g daily and Gentamicin 1mg/ kg three times daily intravenously after Listeria monocytogenes was cultured from the blood
A Gram-positive rod, infects the central nervous system in neonates, pregnant woman and those immunosuppressed by naturally occurring illnesses and by therapeutic agents, including agents such as Infliximab
Summary
A 45-year-old Caucasian woman presented to the emergency department with a two-day history of increasing right lower limb weakness. Her sandals would slip off her right foot due to toe weakness and at times her foot would drag. There were no associated pain, sensory changes or sphincter-related symptoms Two days earlier she had experienced chills, rigors, myalgia and mild headache, but no respiratory or gastrointestinal symptoms. She had excellent clinical response to Infliximab (5 mg/kg) infused on two occasions, most recently a month prior to the current presentation.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: Journal of Clinical Gastroenterology and Treatment
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.